Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00980343 · ClinicalTrials.gov registry record · Phase 2

GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

A Phase 2 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
44
Enrollment target
9
Study locations

NCT00980343 is a Phase 2 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 44 participants, roughly in line with the 41-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target. The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00980343, a Phase 2 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
44 participants
Enrollment target
9
Study locations

Study Summary

This randomized phase II trial is studying how well GDC-0449 works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery. GDC-0449 may be effective in treating patients with glioblastoma multiforme.

Conditions Studied

Adult Glioblastoma Adult Giant Cell Glioblastoma Adult Gliosarcoma Recurrent Adult Brain Tumor

Interventions

  • OTHER laboratory biomarker analysis
  • PROCEDURE therapeutic conventional surgery
  • OTHER pharmacological study
  • DRUG vismodegib

Study Locations (9)

California

  • University of California at Los Angeles - Los Angeles
  • University of California San Francisco - San Francisco

Ohio

  • University Hospitals Case Medical Center - Cleveland
  • Cleveland Clinic Foundation - Cleveland

Georgia

  • Emory University/Winship Cancer Institute - Atlanta

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Michigan

  • Henry Ford Hospital - Detroit

North Carolina

  • Wake Forest University Health Sciences - Winston-Salem

Pennsylvania

  • University of Pennsylvania/Abramson Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2010-02
Est. Completion 2012-06
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00980343

The ClinicalTrials.gov registry entry for NCT00980343 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 41-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Adult Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.

NCT00980343 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, Ohio, Georgia.

Frequently Asked Questions

What is clinical trial NCT00980343 about?

NCT00980343 is a clinical study titled "GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery". This randomized phase II trial is studying how well GDC-0449 works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery. GDC-0449 may be effective in treating patients with glioblastoma multiforme.

What is the current status of trial NCT00980343?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2010-02. Estimated completion is 2012-06.

What conditions does trial NCT00980343 study?

This clinical trial studies the following conditions: Adult Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor.

What interventions are being tested in trial NCT00980343?

The interventions under investigation include: laboratory biomarker analysis (OTHER), therapeutic conventional surgery (PROCEDURE), pharmacological study (OTHER), vismodegib (DRUG).

Who is sponsoring clinical trial NCT00980343?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00980343 being conducted?

This trial has 9 study locations across California, Georgia, Massachusetts, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Adult Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Adult Glioblastoma

All registered trials for this condition

Adult Giant Cell Glioblastoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.